Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
New blood soaking up the float violent move is coming,
from past runs, i see dollars are truly possible here.
Crystal ball glowing 1$ Green AH
Blue skies baby!!!!
you are right about that.
grabbed some on the dip.
KTRA....................................https://stockcharts.com/h-sc/ui?s=KTRA&p=W&b=5&g=0&id=p86431144783
KTRA: Song break for my (languishing) KTRA shares, which is dedicated to the KTRA CEO!!! (One of the most UNUSUAL rock songs of all time!!!)
KTRA: Hey, Bro, if @BROG --- & especially the @BROGW (Warrants) --- can SOAR like they are doing today, despite getting SUED & INVESTIGATED all over the place!!! Then why can't the same happen for KTRA too, eventually???
Good hold or sell I'm at .2
KTRA: Just now getting INVESTIGATED may be the impetus sorely-needed today to send this puppy SOARING.
Investors caught in the Fisker debacle need this guy!
KTRA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Kintara Therapeutics, Inc. Is Fair to Shareholders
9:28 AM ET 4/3/24 | BusinessWire
NEW YORK--(BUSINESS WIRE)--April 03, 2024--
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Kintara Therapeutics, Inc. (NASDAQ: KTRA) and TuHURA Biosciences, Inc. is fair to Kintara shareholders.
Halper Sadeh encourages Kintara shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.
The investigation concerns whether Kintara and its board violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Kintara shareholders; and (2) disclose all material information necessary for Kintara shareholders to adequately assess and value the merger consideration.
On behalf of Kintara shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240403351208/en/
CONTACT: Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
sadeh@halpersadeh.com
zhalper@halpersadeh.com
https://www.halpersadeh.com
SOURCE: Halper Sadeh LLC
Copyright Business Wire 2024
> Dow Jones Newswires
April 03, 2024 09:28 ET (13:28 GMT)
KTRA: Whelp, that sounds fine with me, Colonel INFINITI, Sir!!! Cancer cures at DOLLAR STORE prices, Bro!!!
Yep, run an gun, in an out with 35% gain $$$$$$
KTRA: Looking relatively strong here, Peeps. Outrageously-LOW price for a stock that PR'd news like this puppy did today. So, select one of the following two alternatives: (1.) A glorious 6-to-10-bagger of profits for Investors?? (2.) Or, a magnificent Insiders' toilet flush??
PAST THEIR COMPLIANCE DATE ON MARCH 31ST....DILUTE INTO PUMP AND R/S!!!
heres why https://www.prnewswire.com/news-releases/kintara-therapeutics-and-tuhura-biosciences-enter-into-definitive-merger-agreement-302106737.html
https://www.crweworld.com/article/news-provided-by-accesswire/3349129/kintara-therapeutics-and-tuhura-biosciences-enter-into-definitive-merger-agreement
https://dilutiontracker.com/app/search/KTRA
Whale on $$$$$$$$ weeeeeee
Pull $$$$$$
Reeling $$$$$ fish on $$$$$$$
Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab
https://ih.advfn.com/stock-market/NASDAQ/kintara-therapeutics-KTRA/stock-news/93560120/kintara-therapeutics-announces-expansion-of-rem-00
Announcement soon
Reeling $$$$$ tips down and reeling $$$$)
KINTARA
Therapeutics
Developing Advanced Oncology Therapies for Rare Unmet Medical Needs
Corporate Presentation
August 2023
Copyright © 2022 Kintara Therapeutics, Ir
EG
Robert Hoffman CEO
Late-stage Oncology Company with Two De-Risked Product Candidates
VAL-083: A first-in-class small molecule with unique MOA (MW = 146)
• Pivotal, pre-eminent GBM AGILE International registrational study for three GBM patient subtypes initiated January 2021. A total of 45 sites across US, Canada and Europe.
• ~$1B' market opportunity in lead program: Glioblastoma Multiforme (GBM)
- Multiple shots on goal via parallel enrollment of three GBM patient subtypes
- Over 1,200 patient safety database via ~40 prior studies
REM-001: 2nd generation photodynamic therapy platform
• National Institutes of Health grant awarded June 2023
• 15-patient confirmatory study to start this quarter (3Q 2023)
• ~$500M-market in lead program: Cutaneous Metastatic Breast Cancer
- Extensive Phase 2/Phase 3 efficacy data (80% complete responses across four trials)
- Over 1,100 patient safety database
Multiple follow-on indications with existing orphan designations and/or approved INDs
*Charles River Associates April 2018
EG
Robert Hoffman CEO
Photodynamic Therapy Mechanisms of Action
Light
Energy Source
Necrosis
+
+
10,
Photosensitizen
Catalyst to Activate, Absorb &
Transfer Energy to Oxygen in Cells
Oxygen in Cell
Converted to ROS by Energy Transfer
Reactive 02 (ROS)
Created by
Energy Transfer
PDT induces elimination of diseased cells by
immune response, apoptosis, antiangiogenesis and necrosis
Apoptosis
Antiangiogenic / Anti-vascular
Vascularized,
POT Impairs Vessel
Anglogenic Tumor Function to Cut Off
Blood Supply
Tumor Shrinks
T - Cell Response
Local POT
Tumor
Diseased Cell Death
ROS Provides
Mechanism of Action
Antigen
Metastic
marin
Enzymatic Digestion and
Phagocytosis of Apoptotic
EG
Robert Hoffman CEO
Complete Response Rate of Evaluable Lesions
100
80
60
40
20
71%
CA008
REM-001: High Response Rates in CMBC
97%
86%
80%
54%
• REM-001
= Control
????
Combined
Prior Clinical Trials
Second Generation Photodynamic Therapy
• Light activated cancer therapy
Extensive data from prior Phase 2/Phase 3 clinical trials
• 149 patients treated in 4 trials
- 80% complete response rate in 674
evaluable lesions
Localized Outpatient Treatment
• IV drug infusion accumulates in tumors
• Activated by simple red light
Safety database ~1,100 patients
Previous trial experience used to optimize current trial design
EG
Robert Hoffman CEO
REM-001: CMBC Development Plan
Development plan optimized for success while minimizing cost
• Phase 3 ready
• Initial open-label, 15-patient study to confirm lower dose and optimize trial design
• Leverages prior data indicating lower dose can improve outcome
- Faster healing
- Less photosensitivity
• De-risks full Phase 3 study
IND reactivated August 2022
Fast Track designation received from the FDA in November 2022
National Institutes of Health Grant awarded June 2023
BG
3 Fast track Drug Designations From FDA
1 - 3 Types of Glioblastoma - $ 1.0 B Market & 1 Metastatic Breast Cancer $ 500 Market
wait till close/thur morn for your answer we shall see
Ain’t skeerd here cosm,lifw started down here
Hey TCON was down here at this level
I’ve added big
descending wedges are normally very big movers
moon market just mention this lol
Right sector $$$$
Followers
|
64
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1415
|
Created
|
01/25/13
|
Type
|
Free
|
Moderators |
https://www.kintara.com/
Kintara Therapeutics is focused on developing unique anti-cancer compounds, supported by a strong scientific rationale for development in indications with established biomarkers, and where patients are failing, or are unable to tolerate, current therapies.
VAL-083 is a "first-in-class" small molecule chemotherapeutic. Its unique structure provides many valuable benefits, including the targeting of DNA for its therapeutic effect and its ability to cross the blood brain barrier, critical for activity against central nervous system (CNS) tumors.
VAL-083 has completed Pre-Clinical, Phase I and II trials for the treatment of bevacizumab-refractory glioblastoma multiforme (GBM) and is currently being studied in two Phase II biomarker-driven clinical trials for unmethylated-MGMT GBM.
We are also pursuing the development of VAL-083 in the treatment of ovarian cancer.
REM-001 has broad utility for the treatment of serious cutaneous oncology indications. REM-001 has been previously studied in four Phase 2 and/or Phase 3 clinical trials in patients with cutaneous metastatic breast cancer (“CMBC”), who had previously received chemotherapy and/or failed radiation therapy.
Zacks Small-Cap Research
https://s27.q4cdn.com/906368049/files/News/2021/Zacks_SCR_Research_10112021_KTRA_Vandermosten.pdf
Based on our DCF model and a 15% discount rate, Kintara Therapeutics is valued at approximately $5.25 per share. Our model applies a 60% probability for VAL-083 in unmethylated GBM, a 50% probability in methylated GBM and a 50% probability of approval and commercialization in REM-001 for CMBC. The model includes contributions from the United States and Europe. Other regions will be included upon further clarity.
Shares Outstanding (mil) 43.2
Current Price (10/8/2021) $0.77
Valuation $5.25.
11/03/21
Thanks to its promising pipeline and $0.88 share price, 5-star analyst Michael King, of
H.C. Wainwright, sees an attractive entry point for investors.
“We are bullish about KTRA shares for the following five reasons
: (1) The GBM AGILE trial tests VAL-083 in
all three subtypes of GBM, allowing for multiple opportunities for VAL-083 to prove its
efficacy against phenotypically distinct types of the disease.
(2) VAL-083 is a bifunctional
alkylating agent that crosses the blood brain barrier and exhibits very favorable pharmacologic
properties relative TMZ; fulfilling the need for systemic availability in the brain.
(3) VAL-083
has an established favorable safety record, both from initial trials and prior clinical use in
multiple indications.
(4) Dire unmet need in GBM may present relatively low bar for approval.
(5) Phase 3 ready REM-001 is an additional bonus which is not factored into our valuation
assumptions and could potentially deliver value to shareholders while providing a backstop
against downside,” King explained.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |